Drug Discovery

Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals.

China’s NMPA approves Sanofi’s rare haematologic disease treatments

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease treatments, Qfitlia (fitusiran) and Cablivi (caplacizumab), for patients with haemophilia and acquired thrombotic thrombocytopenic purpura (aTTP) respectively.

Formycon and Zydus sign exclusive agreement for FYB206 supply

Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), in Canada and the US.

Inductive Bio gains $21m ARPA-H funds for drug prediction models

New York City-based tech company Inductive Bio has secured up to $21m from the US Advanced Research Projects Agency for Health (ARPA-H) to lead the development of AI drug toxicity prediction models, aimed at improving drug safety assessment and minimising reliance on animal testing.

Agilent and Monash University Malaysia to set up biodiscovery hub

Agilent Technologies has expanded its collaboration with Monash University Malaysia (MUM) for the establishment of the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub.

FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL

Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for the expanded use of Jaypirca (pirtobrutinib) tablets, in 100mg and 50mg doses, to treat adults with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

AGC Biologics to expand cell line development with ATUM partnership

AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM for integrating the Leap-In transposase expression platform into its services.

Citizen Health and UCB collaborate for epilepsy drug development

Citizen Health has entered a multi-year strategic partnership with UCB for expediting drug development across five rare diseases and epilepsy.

Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status

Solid Biosciences has secured the US Food and Drug Administration (FDA) rare paediatric disease designation for SGT-212, its investigational gene therapy targeting Friedreich’s ataxia (FA).